Form 4: United Therapeutics COO sells 22,500 shares

United Therapeutics President and COO Michael Benkowitz exercised options and sold 22,500 shares under a Rule 10b5-1 plan on 11/17/2025.

Summary

• President and COO Michael Benkowitz executed a pre-planned series of option exercises and open-market sales on 11/17/2025 under a Rule 10b5-1 plan entered on 08/07/2024.
• Exercised 14,625 options at $135.42 (Trust (2)) and immediately sold 14,625 shares at $470.4336.
• Exercised 2,625 options at $146.03 and 5,250 options at $146.03 (Trust (3)) and immediately sold all 7,875 resulting shares at $470.4336.
• Total sold: 22,500 shares at $470.4336 per share; all sales were from trusts in which the reporting person has beneficial ownership.
• Post-transaction common stock directly held: 2,648 shares (Direct).
• Remaining stock options post-transaction: 12,000 options at $135.42 (Trust (2)) and 37,690 options at $146.03 (Trust (3)); one $146.03 grant shows 0 remaining.
• Options involved were exercisable since 03/15/2023 and have expiration date 03/15/2026.
• Form signed by attorney-in-fact (John S. Hess, Jr.) on 11/18/2025 under Power of Attorney.

Sentiment

Score: 5

Explanation: Neutral overall; while a sizable insider sale by the COO can be viewed cautiously, the 10b5-1 plan and substantial remaining option holdings temper negative interpretation.

Positives

• Sales executed under a pre-established Rule 10b5-1 plan dated 08/07/2024, reducing concerns about opportunistic timing.
• Significant remaining option exposure post-transaction (12,000 at $135.42 via Trust (2) and 37,690 at $146.03 via Trust (3)) indicates continued alignment with shareholder outcomes.
• Executive retains 2,648 shares directly following the transactions.

Negatives

• Senior executive sold 22,500 shares on 11/17/2025, which can signal reduced near-term exposure to common equity.
• All shares acquired from option exercises were sold the same day, suggesting transactions were primarily liquidity/diversification-driven rather than accumulation.

Future Outlook

No forward-looking guidance provided; disclosure is limited to pre-planned insider option exercises and share sales under a Rule 10b5-1 plan.

Management Comments

• Transactions (option exercises and subsequent sales) were executed pursuant to a Rule 10b5-1 trading plan entered on 08/07/2024.
• Trust (2): options exercised and resulting shares sold were held in a trust of which the reporting person and spouse are co-trustees with shared voting and investment power.
• Trust (3): options exercised and resulting shares sold were held in a trust for family members, over which the reporting person has sole voting and investment power.

Industry Context

Pre-planned insider transactions under Rule 10b5-1 are standard practice in the biopharma industry to facilitate diversification and mitigate trading window/timing concerns; such filings typically do not reflect changes to company fundamentals.

Comparison to Industry Standards

• Use of Rule 10b5-1 plans by senior executives aligns with common governance practices at large-cap biopharma peers (e.g., Amgen, Gilead, Regeneron) to structure periodic sales and reduce perceptions of opportunistic trading.
• Same-day exercise-and-sell transactions are typical among executives to cover taxes and diversify concentrated equity positions; the structure and disclosure are consistent with SEC reporting norms.

Related Party Transactions

• Transactions involved trusts beneficially owned by the reporting person: Trust (2) co-trustees are the reporting person and spouse with shared voting/investment power.
• Trust (3) beneficiaries are family members; the reporting person has sole voting and investment power over the trust.

Stakeholder Impact

• Shareholders may perceive the executive’s sales as routine diversification due to 10b5-1 planning, reducing concern over timing.
• Market sentiment could be modestly affected by the size of the sale (22,500 shares) by a key executive.
• No dilution or change to shares outstanding; transactions were open-market sales of already-issued shares.

Next Steps

• Monitor any subsequent Form 4 filings for additional planned sales under the 10b5-1 plan.
• Note upcoming option expiration on 03/15/2026, which may prompt further exercises/sales prior to expiry.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, insider trading, Rule 10b5-1, stock options, insider sale, Michael Benkowitz, President and COO, biotech, pharmaceuticals, trust ownership